Advanced search
Publication Cover
Journal of Community Hospital Internal Medicine Perspectives Volume 10, 2020 - Issue 6
Journal homepage
1,017
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Intracranial metastasis from prostate adenocarcinoma: a case report and literature review

Suhu LiuDepartment of Internal Medicine, Albert Einstein College of Medicine, New Rochelle, NY, USACorrespondence[email protected]
,
Ahmed Hassaan QaviDepartment of Internal Medicine, Albert Einstein College of Medicine, New Rochelle, NY, USAORCID Iconhttps://orcid.org/0000-0003-2219-2536
ORCID Icon,
Yoel KimDepartment of Internal Medicine, Albert Einstein College of Medicine, New Rochelle, NY, USA
,
Prasanta BasakDepartment of Internal Medicine, Albert Einstein College of Medicine, New Rochelle, NY, USA
&
Stephen JesmajianDepartment of Internal Medicine, Albert Einstein College of Medicine, New Rochelle, NY, USA
Pages 583-586 | Received 23 Jun 2020, Accepted 13 Aug 2020, Published online: 29 Oct 2020

References

  • Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62:3–12.
  • Tremont-Lukats IW, Bobustuc G, Lagos GK, et al. Brain metastasis from prostate carcinoma: the M. D. Anderson cancer center experience. Cancer. 2003;98:363–368.
  • Hatzoglou V, Patel GV, Morris MJ, et al. Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging. 2014;24:161–166.
  • Kendal WS, Mai KT. Histological subtypes of prostatic cancer: a comparative survival study. Can J Urol. 2010;17:5355–5359.
  • Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 2017;7:a030452.
  • Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746.
  • James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177.
  • Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39–46.
  • Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
  • Caffo O, Veccia A, Fellin G, et al. Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. J Neurooncol. 2013;111:163–167.
  • Laigle-Donadey F, Taillibert S, Mokhtari K, et al. Dural metastases. J Neurooncol. 2005;75:57–61.
  • Lynes WL, Bostwick DG, Freiha FS, et al. Parenchymal brain metastases from adenocarcinoma of prostate. Urology. 1986;28:280–287.
  • Schaller B, Merlo A, Kirsch E, et al. Prostate-specific antigen in the cerebrospinal fluid leads to diagnosis of solitary cauda equina metastasis: a unique case report and review of the literature. Br J Cancer. 1998;77:2386–2389.
  • Macedo F, Ladeira K, Pinho F, et al. Bone Metastases: an Overview. Oncol Rev. 2017;11:321.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.